초록 ▼

An implantable analyte sensor including a sensing region for measuring the analyte and a non-sensing region for immobilizing the sensor body in the host. The sensor is implanted in a precisely dimensioned pocket to stabilize the analyte sensor in vivo and enable measurement of the concentration of t

An implantable analyte sensor including a sensing region for measuring the analyte and a non-sensing region for immobilizing the sensor body in the host. The sensor is implanted in a precisely dimensioned pocket to stabilize the analyte sensor in vivo and enable measurement of the concentration of the analyte in the host before and after formation of a foreign body capsule around the sensor. The sensor further provides a transmitter for RF transmission through the sensor body, electronic circuitry, and a power source optimized for long-term use in the miniaturized sensor body.

대표청구항 ▼

What is claimed is: 1. An electrochemical glucose sensor comprising a three-electrode system, the sensor comprising: an electrochemical cell comprising a working electrode, reference electrode, and counter electrode; and a potentiostat that controls the potential between the working and reference e

What is claimed is: 1. An electrochemical glucose sensor comprising a three-electrode system, the sensor comprising: an electrochemical cell comprising a working electrode, reference electrode, and counter electrode; and a potentiostat that controls the potential between the working and reference electrodes, wherein the potentiostat sets a low voltage limit at which the counter electrode of the glucose sensor reacts with reducible species, other than oxygen, when oxygen becomes limited and at which no substantial bubble formation occurs, wherein the potentiostat comprises an operational amplifier comprising: (i) a first input coupled to the reference electrode; (ii) a second input coupled to a reference voltage source; and (iii) an output coupled to the counter electrode, wherein the reference voltage source is set to a voltage value relative to battery ground such that the low voltage limit at the counter electrode causes the counter electrode to react with reducible species, other than oxygen, when oxygen becomes limited, and substantial bubble formation does not occur at the counter electrode. 2. The sensor of claim 1, wherein the reference voltage setting is between about +0.6V and +0.8V with respect to battery ground. 3. The sensor of claim 2, wherein the reference voltage setting is about +0.7V with respect to battery ground. 4. The sensor of claim 1, wherein the electrochemical cell is configured and arranged for transcutaneous implantation. 5. The sensor of claim 1, further comprising an RF module, wherein the RF module is operably connected to the potentiostat. 6. The sensor of claim 5, further comprising a receiver configured to receive RF transmissions from the RF module. 7. The sensor of claim 6, wherein the receiver comprises a display configured to display sensor data. 8. The sensor of claim 1, wherein the potentiostat comprises a second operational amplifier comprising: (i) a first input coupled to the working electrode; (ii) a second input coupled to a working voltage source; and (iii) an output coupled to the working electrode through a resistor, wherein the potential between the working and reference electrodes is determined by the potential of the working voltage source and reference voltage source. 9. An electrochemical glucose sensor comprising a three-electrode system, the sensor comprising: an electrochemical cell comprising a working electrode, reference electrode, and counter electrode; and a potentiostat that controls the potential between the working and reference electrodes, wherein the potentiostat comprises an operational amplifier comprising: (i) a first input coupled to the reference electrode; (ii) a second input coupled to a reference voltage source; (iii) an output coupled to the counter electrode; (iv) a negative power supply input coupled to a first voltage source; and (v) a positive power supply input coupled to a second voltage source, wherein the reference voltage source, first voltage source and second voltage source set a low voltage limit at which the counter electrode reacts with reducible species, other than oxygen, when oxygen becomes limited, and at which no substantial bubble formation occurs. 10. The sensor of claim 9, wherein the reference voltage setting is between about +0.6V and +0.8V with respect to battery ground. 11. The sensor of claim 9, wherein the reference voltage setting is about +0.7V with respect to battery ground. 12. The sensor of claim 9, wherein the negative power supply input is set to a voltage of battery ground. 13. The sensor of claim 9, wherein the potentiostat comprises a second operational amplifier comprising: (i) a first input coupled to the working electrode; (ii) a second input coupled to a working voltage source; and (iii) an output coupled to the working electrode though a resistor, wherein the potential between the working and reference electrodes is determined by the potential of the working voltage source and reference voltage source. 14. The sensor of claim 9, wherein the electrochemical cell is configured and arranged for transcutaneous implantation. 15. The sensor of claim 9, further comprising an RF module, wherein the RF module is operably connected to the potentiostat. 16. The sensor of claim 15, further comprising a receiver configured to receive RF transmissions from the RF module. 17. The sensor of claim 16, wherein the receiver comprises a display configured to display sensor data. 18. An electrochemical glucose sensor comprising a three-electrode system, the sensor comprising: an electrochemical cell comprising a working electrode, reference electrode, and counter electrode; and a potentiostat that controls the potential between the working and reference electrodes, wherein the potentiostat comprises a current limiter configured to limit the current through at least one of the counter or working electrodes preventing bubble formation from occurring and allow sufficient current through the counter electrode such that it reacts with reducible species, other than oxygen, when oxygen becomes limited. 19. The sensor of claim 18, wherein the electrochemical cell is configured and arranged for transcutaneous implantation. 20. The sensor of claim 18, further comprising an RF module, wherein the RF module is operably connected to the potentiostat. 21. The sensor of claim 20, further comprising a receiver configured to receive RF transmissions from the RF module. 22. The sensor of claim 21, wherein the receiver comprises a display configured to display sensor data. 23. An electrochemical glucose sensor comprising a three-electrode system, the sensor comprising: an electrochemical cell comprising a working electrode, reference electrode, and counter electrode; and a potentiostat that controls the potential between the working and reference electrodes, the potentiostat comprises an operational amplifier comprising: (i) a first input coupled to the reference electrode; (ii) a second input coupled to a reference voltage source; (iii) an output coupled to the counter electrode; and (vi) a voltage offset input coupled to an offset voltage source, wherein the offset voltage source sets a low voltage limit at which the counter electrode reacts with reducible species, other than oxygen, when oxygen becomes limited, and at which no substantial bubble formation occurs. 24. The sensor of claim 23, wherein the voltage applied to the voltage offset input is set to battery ground. 25. The sensor of claim 23, wherein the electrochemical cell is configured and arranged for transcutaneous implantation. 26. The sensor of claim 23, further comprising an RF module, wherein the RF module is operably connected to the potentiostat. 27. The sensor of claim 26, further comprising a receiver configured to receive RF transmissions from the RF module. 28. The sensor of claim 27, wherein the receiver comprises a display configured to display sensor data.